EGFR and neoplasm: Given that SIAH is the most downstream and evolutionary conserved enzyme in the tumor-driving EGFR/HER2/RAS pathway, persistent high SIAH expression in the RCB tumors post-NACT correlates with continued residual tumor growth propelled by rapidly expanding chemo-resistant tumor clones, relating to tumor relapse.